Search alternatives:
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
601
-
602
-
603
-
604
-
605
-
606
-
607
-
608
Replication data set: Variability and correlations decrease during task states in human fMRI data.
Published 2020“…<p>We successfully replicated results from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007983#pcbi.1007983.g003" target="_blank">Fig 3</a> using our held-out cohort of 176 subjects. …”
-
609
-
610
-
611
-
612
-
613
-
614
-
615
-
616
Human Embryonic Stem Cell-Derived Mesenchymal Stromal Cells Decrease the Development of Severe Experimental Autoimmune Uveitis in B10.RIII Mice
Published 2017“…<p><i>Purpose</i>: We investigated the effect of exogenously administered human embryonic stem cell-derived mesenchymal stromal cells (hESC-MSCs) in experimental autoimmune uveitis (EAU) in B10.RIII mice, a murine model of severe uveitis.…”
-
617
-
618
The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of non-caloric saccharin solution.
Published 2013“…<p>Ezlopitant (5 and 10 mg/kg) significantly decreased consumption of the non-caloric 0.2% saccharin solution compared to vehicle. …”
-
619
The NK1-receptor antagonist ezlopitant significantly and selectively decreases voluntary intake of both sucrose and ethanol.
Published 2013“…<p>Ezlopitant decreased consumption of 5% sucrose (<b>A</b>), whereas only the highest dose of ezlopitant (10 mg/kg) decreased consumption of 20% ethanol (<b>B</b>). …”
-
620
<i>In vivo</i> treatment with entinostat decreases Foxp3 expression in Tregs and inhibits Tregs function.
Published 2012“…Cells were harvested from spleens and lymph nodes. A, <i>In vivo</i> entinostat treatment decreased the expression level of Foxp3 in CD4<sup>+</sup>Foxp3<sup>+</sup> (Treg) cells. …”